Costo efectividad del antibiótico oral vs. Local en mujeres no gestantes con flujo vaginal sugestivo de vaginosis bacteriana

Jorge Díaz-Rojas, Mario García-Molina, Liliana Chicaíza-Becerra, Alexander Moreno-Calderón, Victor Prieto-Martínez, Hernando Gaitán-Duarte, Ariel Ruiz-Parra, Andrea Rodriguez-Hernández, Carlos Rincón-Rodriguez and José Urrego-Novoa

Econógrafos, Escuela de Economía from Universidad Nacional de Colombia, FCE, CID

Abstract: Objective: To estimate the cost-effectiveness of local vs. oral antibiotic in non-pregnant women with vaginal discharge suggestive of bacterial vaginosis.

Methods: We compared four combinations of antibiotics for the first option and for the treatment of clinical failure: vaginal clindamycin and tinidazol PO, single dose; vaginal clindamycin and secnidazol PO, single dose; tinidazol PO, single dose y vaginal clindamycin; secnidazol PO, single dose, and vaginal clindamycin. A Markov model was built in TreeAge® to represent the natural history of bacterial vaginosis. Treatment changes in the face of recurrence without adverse events where modeled separately as a decision tree. The perspective was that of the health system, including all direct costs. All monetary amounts were expressed in Colombian pesos of 2010. The outcome was clinical improvement. Effectiveness, security, persistence and recurrence data were extracted from the literature. The incremental cost-effectiveness ratio was calculated; univariate and probabilistic sensitivity analyses were performed.

Results: Both for the general and the particular cases, treatment with vaginal clindamycin as the first choice and tinidazole PO, single dose, to treat recurrence and persistence with adverse events is a dominant strategy because it is less costly and more effective than the other treatment regimes evaluated. Per 1.000 patients, the cost of the dominant alternative is $ 16.795.411 COP with 985,6 clinical improvements in the general case and $ $ 23.979.230 COP with 903,4 clinical improvements in the particular case.

Conclusion: Vaginal clindamycin as the first choice for treatment of bacterial vaginosis and tinidazole PO, single dose, to treat recurrence and persistence with adverse events of clindamycin is cost effective in Colombia. The results were robust to variations in the parameters of the model.

Keywords: Cost benefit analysis; Cost-effectiveness; Health economics; bacterial vaginosis; infection (search for similar items in EconPapers)
JEL-codes: D61 I10 I12 I19 (search for similar items in EconPapers)
Pages: 41
Date: 2012-07
References: Add references at CitEc
Citations:

Downloads: (external link)
https://fce.unal.edu.co/media/files/doc__escuela_de_economa_n_38_daz_et_al.pdf

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:col:000176:022968

Access Statistics for this paper

More papers in Econógrafos, Escuela de Economía from Universidad Nacional de Colombia, FCE, CID Contact information at EDIRC.
Bibliographic data for series maintained by Facultad de Ciencias Económicas Unal ().